Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Carboplatin + Pembrolizumab + Pemetrexed & Non-small-cell lung cancer (NSCLC) (Non-squamous Cell Carcinoma), the US Pembrolizumab label includes an indication for pembrolizumab in the combination Carboplatin + Pembrolizumab + Pemetrexed for the first‑line treatment of patients with metastatic Non-small-cell lung cancer (NSCLC) (Non-squamous Cell Carcinoma) irrespective of PD‑L1 expression, based initially on KEYNOTE‑021 (cohort G1) with accelerated approval, later supported by KEYNOTE‑189.
[EMA/European Commission approval](brain://QMGe2vnxWkWiArAahJp9aA…